Waldencast plc, through its subsidiary Obagi Medical, has announced a collaboration with Platinum Dermatology Partners as part of the Aesthetics Leadership with Obagi's Hyaluronic Acid (ALOHA) Program. This partnership aims to generate real-world evidence for Obagi® saypha® MagIQ™, an innovative injectable developed using proprietary MACRO Core Technology. Platinum providers will participate in clinical initiatives and structured evaluations to translate FDA trial data into everyday practice, with initial findings set to be presented at industry conferences and the annual Platinum Summit. The collaboration underscores Waldencast's commitment to integrating robust clinical evidence and education into the launch of new skincare and aesthetic solutions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Waldencast plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9642103) on January 26, 2026, and is solely responsible for the information contained therein.